To provide a basis for drug selection, as well as safe and rational use of drugs, Mini health technology assessment was used for 4 antiangiogenic agents for the treatment of advanced NSCLC (bevacizumab, ramucirumab, anlotinib, recombinant human endostatin).
Mini health technology assessment was conducted for the 4 mentioned antiangiogenic agents based on ten aspects, such as pharmaceutical characteristics, effectiveness, safety, economy, medical insurance, national essential drug, storage conditions, expiration date, global use and corporate credibility.
Based on the above evaluation criteria, the scores of the four antiangiogenic agents ranged 61~72. The difference in scores was mainly in terms of effectiveness, safety, economy, and storage conditions. Arotinib scored high in the treatment of small cell lung cancer, and was recommended in the drug selection list of medical institutions.
Mini health technology assessment is a multi-dimensional evaluation of drugs, providing basis for hospital drug selection, safe and rational use. It is of relatively high promotion value.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |